Drug Combination Details
| General Information of the Combination (ID: C16622) | |||||
|---|---|---|---|---|---|
| Name | Resveratrol NP Info | + | ABT-737 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MOLT-4 | CVCL_0013 | Adult T acute lymphoblastic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells. Toxicol In Vitro. 2017 Aug;42:38-46. | |||
